1[1]Schwartz CG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recunrent ischenic events in acute coronary syndromes:the MIRACL study: a randomized controlled trial[J]. JAMA, 2001,285:1711-1718.
2[2]Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care(RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival[J] .JAMA,2001,285:430-436.
3[3]David D, Waters MD. Early pharmacologic intervention and plaque stability in acute coronary syndromes [J]. Am J Cardiol, 2001, 88 (Suppl): 30K-36K.
4[4]Kaesemeyer WH, Caldwell RB, Huang JZ, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions[J] .J Am Coil Caidiol, 1999,33:234-241.
5[5]Tamai O, Matsnoka H, Itachc H, et al. Single LDL apharesis improves endothelium-dependent vasodilation in hypercholesterolemic humans[J]. Circulation, 1997,95:76-82.
6[6]O' Driscoll G, Green D, Taylor RR, et al. Simvastatin, an HMG-Coenzyme A reductase inhibitor improves endothelial function within 1 month[J]. Circulation, 1997,95:1126-1131.
7[7]Feron O,Dessy C,Desager JP, et al. HMG-CoA reductase inhibition promotes endothelial cell nitric oxide synthase activation through a decrease in caveolin abundance[J]. Circulation, 2000,103:113-118.
8[8]Selwyn AP, Kinlay S, Libby P, et al. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease[J]. Circulation, 1997,95:5-7.
9[9]Lacostc L, Larn JYT, Hung J, et al. Hypexlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction[J]. Circulation, 1995,92:3172-3177.
10[10]ColliS,EliginiS, Lalli M, et al. Statins inhibit tissue factor in cultured human macrophages[J]. Arterioscler Thromb Vasc Biol, 1997,30:1212-1217.
同被引文献42
1Steen DK,Ravn HB,Falk E. Insight into the pathophysiology of unstable coronary artery disease[J]. Am J Cardiol, 1997,80(5A) :5-9.
2Maclsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque[J] .J Am Coll Cardiol, 1993,22:1228-1241.
3Pedro R M, Erling F,Igor F P,et al.Macrophage infiltration in acute coronary syndrome[J],Circulation, 1994,90:775-778.
4Prediman KS,Erling F,Juan JB,et al.Human monocyto-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques:potential role of matrix-degrading metalloproteinases and implications for plaque rupture[J],Circulation, 1995,92:1565-1569.
5Capurso A.The promise M statins[J] .Ital Heart J,2001,2(Suppl 3):224-229.
6Galis ZS,Sukhova GK,Lark MW,et al.Increased expression of matrixmetalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques[J] .J Clin Invest, 1994,94:2493-2503.
7Brown DL,Hibbs MS,Keamey M, et al. Identification of 92kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina[J]. Circulation, 1995,91:2125-2131.
8Moulin B,Cailard S.Kidney and Statins[J].Ann Endocrinol,2001,62(1pt 2):121-127.
9Export Panel on Detection, Evaluation and treatment of High blood cholesterol in adults, Executive summary of third repot of the National cholesterol education program(NCEP) export panel on Detection, Evaluation, and treatment of High blood cholesterol in adults treatment panel (Ⅲ)[J].JAMA,2001,285(19):2486-2509.
10Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease[J].N ENGL MED,1995,332(8):481-487.
